FDA Raises Safety, Efficacy Concerns About Dendreon’s Cancer Vaccine Provenge
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee will discuss cerebrovascular accident as a safety signal for Provenge, as well as the biologic’s failure to meet primary efficacy endpoints.
You may also be interested in...
Advisory Committee Votes Favorably On Dendreon’s Prostate Cancer Vaccine
Though questions remain, majority of members find Provenge has “substantial evidence” of efficacy.
Advisory Committee Votes Favorably On Dendreon’s Prostate Cancer Vaccine
Though questions remain, majority of members find Provenge has “substantial evidence” of efficacy.
Sanofi Gains Therapeutic Cancer Vaccine TroVax In Deal With Oxford BioMedica
Announcement of the $690 million deal comes one day ahead of an advisory committee meeting for Provenge, the first therapeutic cancer vaccine to reach FDA.